NCT00732940 - Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

March 31, 2012

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Belimumab 100 mg SC

Belimumab 100 mg SC for 1 injection on Days 0, 7, 14, and then every two weeks.

DRUG

Belimumab 100 mg SC

Belimumab 100mg SC for 2 injections (of 100mg each) on Days 0, 2, and 4, then 100 mg (1 injection) three times per week.

Trial Locations (11)

North Shore-LIJ Health System/Rheumatology, Allergy, Immunology, Lake Success

SUNY Downstate Medical Center, Brooklyn

Rheumatology Associates, Smithtown

Tampa Medical Group, PA, Tampa

STAT Research, Inc., Dayton

Fiechtner Research, Inc., Lansing

Oklahoma Center for Arthritis Therapy & Research, Tulsa

Houston Institute for Clinical Research, Houston

"Hospital Central Igancio Morones Prieto", San Lusi Potosi

Valerious Medical Group Research Center, Long Beach

University of Alabama at Birmingham, Birmingham